Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Discovery
Cancer Discovery

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
    • Journal Press Releases
News in Brief

Anti–PD-1 Therapy OK for Most with HIV

DOI: 10.1158/2159-8290.CD-NB2017-174
  • Article
  • Info & Metrics
Loading

The PD-1 inhibitor pembrolizumab (Keytruda; Merck) poses no significant risks for patients with HIV and cancer, according to interim data from a phase I study presented during the Society for Immunotherapy of Cancer (SITC) conference held last month in National Harbor, MD. The findings suggest that patients with HIV should no longer be excluded from clinical trials testing checkpoint inhibitor therapies for various cancers.

In the ongoing study, investigators are evaluating the safety of pembrolizumab in three cohorts of patients infected with HIV based on CD4 T-cell count (100–199, 200–350, and >350). All patients had relapsed or refractory cancers and were taking HIV antiretroviral therapy (ART). In an interim analysis of 36 patients, HIV remained suppressed in all patients after a median of 12 weeks of treatment.

“As more effective and better-tolerated treatments have become available over the past 20 years, many HIV patients are aging and being diagnosed with a wider variety of cancers,” notes Thomas Uldrick, MD, senior clinician in the HIV and AIDS Malignancy Branch of the NCI's Center for Cancer Research in Bethesda, MD. In particular, they have an increased risk of developing HIV-related cancers—including B-cell lymphomas and Kaposi sarcoma—as well as non–HIV-related solid tumors.

“Cancer is now the leading cause of death in HIV patients,” says Uldrick. “As a result, we need to rethink the way we treat these patients and ensure that they are able to participate in clinical trials when appropriate.”

Due to concerns about the risk of infections and toxicities in patients with a compromised immune system, those with HIV have long been excluded from oncology trials. However, modern HIV treatments can restore immune function in most patients, with minimal adverse effects.

“HIV-positive patients now live as long as most uninfected people, so it no longer makes sense to continue excluding them from clinical trials when they get cancer,” says Edward Kim, MD, chair of Solid Tumor Oncology at Levine Cancer Institute, Carolinas Healthcare System, in Charlotte, NC. “To date, clinical trials have been so exclusionary that we have very little data on how checkpoint inhibitors work in HIV patients.”

The interim data supports recommendations made by an American Society of Clinical Oncology working group, led by Uldrick, stating that eligibility for trials should be based on CD4 T-cell counts, as well as any history of AIDS complications and effective treatment with ART.

Although most of those in the study fared well with pembrolizumab, additional research is needed in select patients, notes Uldrick. For example, one patient who had been previously diagnosed with Kaposi sarcoma (KS) and KS herpesvirus (KSHV)–inflammatory cytokine syndrome died after experiencing a sharp rise in KSHV viral load following pembrolizumab treatment, suggesting that those with KSHV-associated diseases or unexplained viruses require special consideration. In general, however, it's reasonable to prescribe treatment based on CD4 T-cell counts to gauge the risk of opportunistic infections, he says.

“It's become clear that we should not treat HIV patients [with cancer] differently from other cancer patients when it comes to clinical trials,” says Uldrick. “We now need to establish criteria to help us select patients who are healthy enough and would do well in the long run if not for their cancer.” –Janet Colwell

  • ©2017 American Association for Cancer Research.
View Abstract
Next
Back to top

Published OnlineFirst December 13, 2017
doi: 10.1158/2159-8290.CD-NB2017-174

View this article with LENS

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Anti–PD-1 Therapy OK for Most with HIV
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
Citation Tools
Anti–PD-1 Therapy OK for Most with HIV
Cancer Discov December 13 2017 DOI: 10.1158/2159-8290.CD-NB2017-174

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Anti–PD-1 Therapy OK for Most with HIV
Cancer Discov December 13 2017 DOI: 10.1158/2159-8290.CD-NB2017-174
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Early-Detection Sequencing Assays Prove Highly Specific
  • Vision for NCI Outlined by New Director
  • Combo Therapy for Lung Cancer Extends Survival
Show more News in Brief
  • Home
  • Alerts
  • Feedback
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement